Your browser doesn't support javascript.
loading
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Hartmaier, Ryan J; Markovets, Aleksandra A; Ahn, Myung Ju; Sequist, Lecia V; Han, Ji-Youn; Cho, Byoung Chul; Yu, Helena A; Kim, Sang-We; Yang, James Chih-Hsin; Lee, Jong-Seok; Su, Wu-Chou; Kowalski, Dariusz M; Orlov, Sergey; Ren, Song; Frewer, Paul; Ou, Xiaoling; Cross, Darren A E; Kurian, Nisha; Cantarini, Mireille; Jänne, Pasi A.
Afiliación
  • Hartmaier RJ; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Markovets AA; Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Ahn MJ; Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea.
  • Sequist LV; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Han JY; Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea.
  • Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Yu HA; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kim SW; Department of Oncology, University of Uslan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Yang JC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan.
  • Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Republic of Korea.
  • Su WC; Department of Internal Medicine, National Cheng Kung University Hospital, Tainan City, Taiwan.
  • Kowalski DM; Department of Lung Cancer and Thoracic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Orlov S; BioEq, LLC, Saint Petersburg, Russian Federation.
  • Ren S; Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca, Gaithersburg, Maryland.
  • Frewer P; Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Ou X; Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Cross DAE; Oncology Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Kurian N; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Boston, Massachusetts.
  • Cantarini M; Oncology Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Discov ; 13(1): 98-113, 2023 01 09.
Article en En | MEDLINE | ID: mdl-36264123
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2023 Tipo del documento: Article